Zobrazeno 1 - 10
of 882
pro vyhledávání: '"time to progression"'
Autor:
José Presa Ramos, Sofia Tavares, Ana Barreira, Joana Liz Pimenta, Sónia Carvalho, Paulo Carrola, Inês Pinho
Publikováno v:
GE: Portuguese Journal of Gastroenterology, Vol 30, Iss 3, Pp 213-220 (2023)
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocellular carcinoma (HCC). Multiple prognosis factors associated with sorafenib therapy have been described. Objectives: The aim of this work was to evalua
Externí odkaz:
https://doaj.org/article/41871b167b3741c790708d479cb1dcf9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101910- (2023)
Summary: Background: Biomarker-defined patients with smoldering multiple myeloma (SMM) were included in the diagnostic category of multiple myeloma (MM) by the International Myeloma Working Group (IMWG) in 2014. This includes ≥60% bone marrow plasm
Externí odkaz:
https://doaj.org/article/8d3802c38ee7469b8f756f00281f4b70
Autor:
Zi-yi Zhu, Mu Yuan, Pei-Pei Yang, Bo Xie, Jian-zhu Wei, Zhong-qiang Qin, Zhen Qian, Zhao-Ying Wang, Long-Fei Fan, Jing-yu Qian, Yu-lin Tan
Publikováno v:
World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Microwave ablation (MWA) is a potentially curative treatment for unresectable patients with hepatocellular carcinoma (HCC) ≤ 3 cm, while its therapeutic efficacy decreases significantly for HCC > 3cm. Previous studies have demon
Externí odkaz:
https://doaj.org/article/8f5c7d76b5ec4c77b664b060b67a0836
Autor:
Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionAlthough transarterial radioembolization (TARE) using yttrium-90 (90Y) is a treatment option for large hepatocellular carcinoma (HCC), a fraction of patients are ineligible for TARE due to high lung shunt fraction (LSF).MethodsWe evaluate
Externí odkaz:
https://doaj.org/article/9f2e6aef2e784e26a03d68c0a8b821df
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundIntracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a novel rare disease after the 2016 WHO reclassification. Surgery is the main treatment. Postoperative adjuvant radiotherapy is often used, but the effects of different rad
Externí odkaz:
https://doaj.org/article/a367803755cf41029926f58bae083792
Autor:
Nienke van de Kruis, Phyllis van der Ploeg, Jody H.C. Wilting, M. Caroline Vos, Anna M.J. Thijs, Joanne de Hullu, Petronella B. Ottevanger, Christianne Lok, Jurgen M.J. Piek
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101035- (2022)
Objective: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS of the most recent treatment on which the p
Externí odkaz:
https://doaj.org/article/81897c8e0e8b4228992aff841b0b5493
Autor:
Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/d945687fc1ba4b6ca0be33f590f5a185
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 2270-2280 (2021)
In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i + AI from January 2016 through
Externí odkaz:
https://doaj.org/article/c1043d7c86d442009399f44dde435234
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveTo explore the prognostic significance of the stage at which a minimal residual disease (MRD)-negative status is achieved for patients with newly diagnosed multiple myeloma (NDMM) who received autologous hematopoietic stem cell transplantati
Externí odkaz:
https://doaj.org/article/7562177cca2045faadd7a9cb172f9815